The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy

Kidney International

Volumn 81, Issue 7, 2012, Pages 674-683

  Hirst, Jennifer A ^a,b   Taylor, Kathryn S ^a,b   Stevens, Richard J ^a,b   Blacklock, Claire L ^a,b   Roberts, Nia W ^a,b   Pugh, Christopher W ^c   Farmer, Andrew J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Manchester   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ACE inhibitors; diabetes; diabetic nephropathy; microalbuminuria; renin?angiotensin system

Indexed keywords

ALBUMIN; AMLODIPINE; ATENOLOL; CANDESARTAN; CAPTOPRIL; ENALAPRIL; FOSINOPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS MODEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; URINARY EXCRETION;

EID: 84858316646     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.413     Document Type: Article

References (37)

1. Foley RN, Collins AJ. The growing economic burden of diabetic kidney disease. Curr Diab Rep 2009; 9: 460-465.
2. Van Dieren S, Beulens JWJ, Van Der Schouw YT et al. The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17: S3-S8.
3. Hope SI, Gerstein HC, Yusuf S et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
4. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
5. Mogensen CE. Twelve shifting paradigms in diabetic renal disease and hypertension. Diabetes Res Clin Pract 2008; 82(Suppl 1): S2-S9.
6. Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulindependent) diabetic nephropathy. Diabetologia 1993; 36: 1094-1098.
7. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-1418.
8. Newman DJ, Mattock MB, Dawnay ABS et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9: Iii-ivi, xiii-163.
9. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews (Online) 2005. Issue no. 4. Article no. CD004136.
10. Strippoli GFM, Bonifati C, Craig M et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006. Issue no. 4. Article no. CD006257.
11. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 1992; 41: 912-919.
12. Cordonnier DJ, Pinel N, Barro C et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253-1263.
13. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-S155.
14. Crepaldi G, Carraro A, Brocco E et al. Hypertension and non-insulindependent diabetes: A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetologica 1995; 32: 203-208.
15. Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
16. Muirhead N, Feagan BF, Mahon J et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial. Curr Ther Res Clin Exp 1999; 60: 650-660.
17. Ogawa S, Takeuchi K, Mori T et al. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res Clin Exp 2007; 30: 325-334.
18. EUCLID. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
19. AdvanceDe Galan BE, Perkovic V, Ninomiya T et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892.
20. Baba S, Koike T, Makino I et al. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201.
21. Sawaki H, Terasaki J, Fujita A et al. A renoprotective effect of low dose losartan in patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 86-90.
22. Chan JCN, Ko GTC, Leung DHY et al. Long-term effects of angiotensinconverting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
23. Perrin NESS, Jaremko GA, Berg UB. The effects of candesartan on diabetes glomerulopathy: A double-blind, placebo-controlled trial. Pediatr Nephrol 2008; 23: 947-954.
24. DirectBilous R, Chaturvedi N, Sjølie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes three randomized trials. Ann Intern Med 2009; 151: 11-20.
25. Maione A, Navaneethan SD, Graziano G et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro-and macroalbuminuria and other cardiovascular risk factors: A systematic review of randomized controlled trials. Nephrol Dial Transplant 2011; 26: 2827-2847.
26. Riley RD, Gates S, Neilson J et al. Statistical methods can be improved within Cochrane pregnancy and childbirth reviews. J Clin Epidemiol 2011; 64: 608-618.
27. Cochrane handbook for systematic reviews of interventions. September 2009 Version 5.0.2.
28. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
29. Gerstein HC. Diabetes and the hope study: Implications for macrovascular and microvascular disease. Int J Clin Pract Suppl 2001: 8-12.
30. Lambers Heerspink HJ, Gansevoort RT, Brenner BM et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010; 21: 1355-1360.
31. Yudkin JS, Lehman R. Olmesartan, microalbuminuria, and type 2 diabetes. N Engl J Med 2011; 364: 2260; author reply 2-3.
32. Rosen AB. Indications for and utilization of ACE inhibitors in older individuals with diabetes: Findings from the national health and nutrition examination survey 1999 to 2002. J Gen Int Med 2006; 21: 315-319.
33. Blacklock C, Hirst J, Taylor K et al. Evidence for a dose-effect of renin-angiotensin system inhibition on progression of microalbuminuria in type 2 diabetes: A meta-analysis. Diabetic Med 2011; 28: 1182-1187.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
35. Friedrich J, Adhikari N, Beyene J. The ratio of means method as an alternative to mean differences for analysing continuous outcome variables in meta-analysis: A simulation study. BMC Med Res Methodol 2008; 8: 32.
36. Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol 2011; 64: 556-564.
37. Kunz R, Friedrich C, Wolbers M et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.